anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: We introduce selective internal limiting membrane (ILM) peeling, a guideline procedure to determine whether to remove the ILM during vitrectomy for rhegmatogenous retinal detachment (RRD).
STUDY DESIGN: Retrospective case series METHODS: Patients who underwent pars plana vitrectomy for RRD and were followed up for 12 months or longer were included. When vitreous cortex remnants (VCRs) were detected with triamcinolone acetonide, the ILM was removed; otherwise, the ILM was preserved ("selective ILM peeling"). The factors associated with the presence of VCRs and incidence of secondary epiretinal membrane (ERM) were analyzed.
RESULTS: VCRs were detected in 87 of 133 eyes (65.4%) in which the ILM was removed. Younger age, better preoperative visual acuity, and vitreous hemorrhage were negatively correlated with the presence of VCRs. No ERM occurred in the eyes after ILM peeling. Among the eyes with ILM preservation, subclinical ERM was noticed in 4 eyes (8.7%), and 1 eye (2.1%) required additional surgery owing to ERM. ERM occurred more commonly in eyes with the ILM preserved (P = .004). However, no differences in the rate of additional surgeries were found between the 2 groups.
CONCLUSION: Selective ILM peeling offers an alternative option to reduce the burden of ILM peeling or additional surgery.
BACKGROUND: Artificial intelligence (AI) chatbots have the potential to assist individuals with chronic health conditions by providing tailored information, monitoring symptoms, and offering mental health support. Despite their potential benefits, research on public attitudes toward health care chatbots is still limited. To effectively support individuals with long-term health conditions like long COVID (or post-COVID-19 condition), it is crucial to understand their perspectives and preferences regarding the use of AI chatbots.
OBJECTIVE: This study has two main objectives: (1) provide insights into AI chatbot acceptance among people with chronic health conditions, particularly adults older than 55 years and (2) explore the perceptions of using AI chatbots for health self-management and long COVID support.
METHODS: A web-based survey study was conducted between January and March 2023, specifically targeting individuals with diabetes and other chronic conditions. This particular population was chosen due to their potential awareness and ability to self-manage their condition. The survey aimed to capture data at multiple intervals, taking into consideration the public launch of ChatGPT, which could have potentially impacted public opinions during the project timeline. The survey received 1310 clicks and garnered 900 responses, resulting in a total of 888 usable data points.
RESULTS: Although past experience with chatbots (P<.001, 95% CI .110-.302) and online information seeking (P<.001, 95% CI .039-.084) are strong indicators of respondents' future adoption of health chatbots, they are in general skeptical or unsure about the use of AI chatbots for health care purposes. Less than one-third of the respondents (n=203, 30.1%) indicated that they were likely to use a health chatbot in the next 12 months if available. Most were uncertain about a chatbot's capability to provide accurate medical advice. However, people seemed more receptive to using voice-based chatbots for mental well-being, health data collection, and analysis. Half of the respondents with long COVID showed interest in using emotionally intelligent chatbots.
CONCLUSIONS: AI hesitancy is not uniform across all health domains and user groups. Despite persistent AI hesitancy, there are promising opportunities for chatbots to offer support for chronic conditions in areas of lifestyle enhancement and mental well-being, potentially through voice-based user interfaces.
INTRODUCTION: Seladelpar (MBX-8025) is a once-daily administered highly specific PPAR-δ agonist in Phase 3 and extension trials for use in patients with primary biliary cholangitis (PBC).
AREAS COVERED: This review provides background on current treatment options for PBC, and summarizes clinical trial data regarding the safety and effectiveness of seladelpar within the context of these treatments.
EXPERT OPINION: Clinical trials results demonstrate the safety and tolerability of seladelpar use for PBC, including in patients with cirrhosis. The primary composite endpoint (ALP <1.67 times ULN, decrease ≥ 15% from baseline, and TB ≤ULN) was met in 61.7% of the patients treated with seladelpar and in 20% receiving placebo (p < 0.001). Moreover, pruritus - a cardinal and often intractable symptom of PBC - was improved with seladelpar treatment, as were overall quality of life measurements. Improvements in markers of inflammation were likewise observed. These biochemical and clinical findings therefore represent landmark developments in PBC treatment and offer a therapeutic option for PBC.
Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
This is a phase I study in healthy male volunteers, who will be given dexamethasone to suppress their natural cortisol production. 18 will be consented for the study. They will have had a history and a physical examination, blood tests for routine safety, hepatitis C and Human Immunodeficiency Virus (HIV), drug abuse and Electrocardiograms (ECGs). Following the results of these tests and the inclusion/exclusion criteria for the study, they will be admitted to the phase I unit on the first afternoon (Day -1). They will be given dexamethasone at 22.00hrs that evening, and remain in the unit until the end of the period. Further dexamethasone doses will be given at 06:00, 12:00, and 18:00 hours on Day 1 (plus at 22:00 hours in patients given the modified release study drug). Each volunteer will be admitted for 3 periods of approximately 1.5 days, with a washout of 7 days between periods, and they will be randomised to either fast and take a single 20mg dose of immediate release hydrocortisone, to fast and take a single 20mg dose of the study medication, (a modified release hydrocortisone), or to the "fed" group, where they take a single dose of 20mg study medication, and have a highly calorific standardised breakfast. The volunteers will have cannulae to enable one pre-dose blood sample to be taken followed by 24 hour Pharmacokinetic (PK) sampling (modified release) and 12 hour PK sampling for the immediate release period. After these samples have been taken the volunteers will be able to leave the unit. There will be another assessment 3 to 5 days after study period 3 with further blood tests, assessment of any adverse events etc.
Infusion-associated reactions (IARs) have been reported in LAMZEDE-treated patients. In clinical trials 19 (50%) LAMZEDE-treated patients (3 adult and 16 pediatric patients) experienced IARs. Of these 19 patients, 5 (13 % of all patients) required pretreatment in the clinical trials. One LAMZEDE-treated patient in clinical trials discontinued due to recurrent IARs.

The most frequent symptoms of IARs that occurred in >10% of the population were pyrexia, chills, erythema, vomiting, cough, urticaria, rash and conjunctivitis. Similar symptoms were observed in adult and pediatric populations.

Prior to LAMZEDE administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids to reduce the risk of infusion-associated reactions (IARs). However, IARs may still occur in patients after receiving pretreatment.

  * If a severe IAR occurs, discontinue LAMZEDE immediately and initiate appropriate medical treatment. Consider the risks and benefits of readministering LAMZEDE following a severe IAR. Patients may be rechallenged using slower infusion rates. Once a patient tolerates the infusion, the infusion rate may be increased to reach the recommended infusion rate.  

  * If a mild or moderate IAR occurs, consider slowing the infusion rate or temporarily withholding the dose [see Dosage and Administration (2.3)].
The present invention relates to the synthesis of a water-soluble 5 -fluorouracil (5-FU) copper(II) terpyridine (terpy) complex [CuCl(5-FU)(terpy)]. At the end of the study conducted with various types of cancer, it has been observed that the copper(II) complex is specifically effective against colon cancer (cytotoxic, cell-killing effect). It has been understood that the mode of cell death is apoptosis. The complex also showed antimi gratory properties. Finally, the antiangiogenic properties of the complex was also shown by in-ovo CAM test. Considering all these results (cytotoxic, antimigratory, antiangiogenic), it was concluded that the complex is a candidate to be used in the treatment of colon cancer (lead complex/compound).
Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
PURPOSE: A composition containing Chamaecyparis obtuse essential oil extract, compound isolated from the extract for hair growth is provided to be used in a pharmaceutical or cosmetic composition for hair growth without side effects. CONSTITUTION: A composition for hair growth contains Chamaecyparis obtusa essential oil extract or fraction thereof as an active ingredient. The essential oil extract is isolated by steam distillation. The fraction is performed by hexane or ethyl acetate solvent. The fraction is CH-HE-1-6, CH-HE-1-7, CH-HE-2-A,CH-HE-2-B,CH-HE-2-C, CH-HE-2-D,CH-HE-2-E, CH-HE-2-F, or CHHE-2-G. The composition is manufactured in the form of topical application type formulation. The formulation is ointment, lotion, or spray.
An experienced yoga instructor led the 30 minutes yoga condition session which consisted of 5 minutes warm up, 5 minutes breathing exercises, and 20 minutes yoga poses practice. The yoga props were used according to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably.
To provide a film for patch support which has the medicine barrier property and the extensibility while suppressing time and effort and cost in manufacture, and is hard to be torn when exhibiting the extensibility by being pulled.SOLUTION: There is provided a film for patch support that is formed of resin having the medicine barrier property. The film has an uneven structure in which a recess and a protrusion are repeated along a surface. The top of the protrusion and the bottom of the recess are respectively in the flat shape in the cross section. The thickness of the film for patch support is equal to or greater than 5 μm and less than 150 μm. The difference of elevation between the recess and the protrusion is larger than the thickness of the film for patch support. The top of the protrusion and the bottom of the recess that are adjacent to each other are connected to each other by a slope part. Boundary portions between the top of the protrusion and the slope part and between the bottom of the upper part and the slope part are in the curved shape in the cross section. The ratio of the difference of elevation H to the curvature radius R of the curved shape (R/H) is equal to or greater than 0.25 and less than 1.00. The value obtained by doubling the curvature radius R of the curved shape is smaller than the length L in the width direction of the uneven structure.SELECTED DRAWING: Figure 1
The invention discloses a sensitivity relieving lotion for treating facial skin sensitivity symptoms. The sensitivity relieving lotion prepared by dissolving boric acid, hyaluronic acid and allantoin into deionized water is used for treating the facial skin sensitivity symptoms caused by various reasons. In the sensitivity relieving lotion, the concentrations of the boric acid, the hyaluronic acid and the allantoin are 3%, 0.15% and 2% respectively. The 3% of boric acid solution has antibacterial effect and less irritation, can reduce inflammatory mediator exudation and can relieve inflammatory reactions. The hyaluronic acid can form a breathable hydration shell quickly to cover skin surface, so that skin moisture is increased, stratum corneum of skin is softened, active substance absorption and utilization of the stratum corneum of the skin are enhanced, and the skin becomes fine and smooth. The allantoin further enhances the water absorbing capability of the skin, and accordingly, the skin becomes smooth, moistened, soft and elastic. The three ingredients are dissolved in the deionized water to form the sensitivity relieving lotion which is used for treating the facial skin sensitivity symptoms, rebuilding skin screening function and recovering healthy skin.
The invention discloses a natural Chinese wax hair-care pilatory and a preparation method thereof. The natural Chinese wax hair-care pilatory comprises the following raw materials in parts by mass: 10-50 parts of Chinese wax and 90-50 parts of camellia oleosa seed oil. The preparation method comprises the following steps: grinding the Chinese wax into powder; adding the Chinese wax powder into the camellia oleosa seed oil under a water bath condition; after the Chinese wax powder is completely dissolved in the camellia oleosa seed oil, stirring and cooling the mixture to normal temperature to obtain the hair-care pilatory. Through mutual complementation and mutual promotion of the pure natural properties and the specific effects of the raw materials (including Chinese wax, camellia oleosa seed oil and other plant extracts) used in the natural Chinese wax hair-care pilatory, the natural Chinese wax hair-care pilatory has the advantages of small side effect, high safety, nontoxicity, innocuousness, non-carcinogenicity and the like as compared with a chemosynthetic pilatory. Compared with like natural medicinal pilatory, the natural Chinese wax hair-care pilatory has the advantages that the formula is simple and clear and the preparation process is simple, convenient and easy to implement. In addition, Chinese wax and camellia oleosa seed oil are applied to the pilatory for the first time so as to enlarge the range of plant source hair growth products. Experiments prove that the pilatory provided by the invention has the effect of promoting hair growth.
Provided herein is a gene therapy for  CSRP3  (Cysteine and Glycine Rich Protein 3)-related gene deficits associated with cardiomyopathy,  e.g.  using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
Increasing evidence exist regarding the role of diet in the pathogenesis of inflammatory bowel diseases. One possible mechanism for the effect of diet on intestinal inflammation is modification of the gut microbial composition. However, the relationship between diet, the microbiome and intestinal inflammation is still vague.

The investigators plan to perform a crossover clinical trial. Seventy ulcerative colitis patients post restorative proctocolectomy (pouch) will be randomly allocated into two short-term (one week) dietary interventions, the Mediterranean diet and the specific carbohydrate diet, to assess which diet has the required influence (i.e. increased diversity, decrease in specific pathobionts and increase in "anti-inflammatory" taxa) on the gut microbiome of each participant. Based on this assessment, each participant will be treated by a personally-tailored diet for up to one year, during which microbial composition, clinical parameters, and quality of life will be assessed.
The aim of this prospective observational study is to determine the prevalence of ipilimumab lung toxicity defined by a significant decline of the diffusing capacity of the lung for carbon monoxide (DLCO) and/or forced vital capacity (FVC) in patients with MM.

Patients aged over 18 years with an established diagnosis of MM who are treated and followed up at the Department of Dermatology are asked to participate in the study after the indication for treatment with ipilimumab is given by the interdisciplinary skin tumorboard conference. After written informed consent is obtained, patients undergo a baseline evaluation (V1) including a medical history, physical examination, laboratory analyses (hemoglobin, leucocytes count, C-reactive protein, and pulmonary function tests (PFTs) with spirometry and measurement of DLCO. Thereafter, the first dose of ipilimumab (3mg/kg) is given intravenously over a period of 90 minutes without premedication. The subsequent three doses of ipilimumab are administered three weekly with analogue dose. Subsequent study visits (V2, V3, V4) including PFTs are scheduled on the same day as ipilimumab is administered. Thus, study visits are thoroughly adapted to the clinical visits, which is given by the administration of ipilimumab (total of four injections each separated by three weeks). In case of new respiratory symptoms during the study period, additional PFTs and a high-resolution computed tomography (HR-CT) of the chest are performed. In case of early study termination during follow-up pulmonary function test values which are already obtained are used for the final analysis.
Participants will receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
Devices will be programmed by our study coordinator to provide a sham signal or the experimental signal. The location of the TENS electrodes will be determined by the location of the pain with the goal of placing the unit at the top of the dermatological level corresponding to the pain. The study coordinator will assist each subject to place the device appropriately. Treatment will be administered for 1 hour per day for 4 weeks.
The invention relates to a novel influenza virus strain and to the influenza virus vaccine containing said strain. The new strain, which is the DNCM No. I-099 strain, is prepared by recombination of the influenza A/PR/8/34 virus strain with the influenza A/California/10/78 (CNCM No. I-098) virus strain. The vaccine is prepared by allowing the CNCM No. I-099 strain to grow in the allantoic cavity of fertile hen's eggs, harvesting and freeze-drying the yielded virus material. The strain and the vaccine deriving therefrom are valuable for the immunization against influenza caused by influenza type A (H1N1) virus strains.
Deaths in preterm infants after infusion of intravenous fat emulsion have been reported in the medical literature2. 

Autopsy findings included intravascular fat accumulation in the lungs. Treatment of premature and low birth weight infants with intravenous fat emulsion must be based upon careful benefit-risk assessment. Strict adherence to the recommended total daily dose is mandatory; hourly infusion rate should be as slow as possible in each case and should not in any case exceed 1 g fat/kg in four hours. Premature and small for gestational age infants have poor clearance of intravenous fat emulsion and increased free fatty acid plasma levels following fat emulsion infusion; therefore, serious consideration must be given to administration of less than the maximum recommended doses in these patients in order to decrease the likelihood of intravenous fat overload.

The infant's ability to eliminate the infused fat from the circulation must be carefully monitored (such as serum triglycerides and/or plasma free fatty acid levels).

The lipemia must clear between daily infusions.

Caution should be exercised in administering of Intralipid 20% (A 20% Intravenous Fat Emulsion) to patients with severe liver damage, pulmonary disease, anemia, or blood coagulation disorders, or when there is danger of fat embolism.
OBJECTIVE: Simultaneous activation of β2- and β3-adrenoceptors (ARs) improves whole-body metabolism via beneficial effects in skeletal muscle and brown adipose tissue (BAT). Nevertheless, high-efficacy agonists simultaneously targeting these receptors whilst limiting activation of β1-ARs - and thus inducing cardiovascular complications - are currently non-existent. Therefore, we here developed and evaluated the therapeutic potential of a novel β2-and β3-AR, named ATR-127, for the treatment of obesity and its associated metabolic perturbations in preclinical models.
METHODS: In the developmental phase, we assessed the impact of ATR-127's on cAMP accumulation in relation to the non-selective β-AR agonist isoprenaline across various rodent β-AR subtypes, including neonatal rat cardiomyocytes. Following these experiments, L6 muscle cells were stimulated with ATR-127 to assess the impact on GLUT4-mediated glucose uptake and intramyocellular cAMP accumulation. Additionally, in vitro, and in vivo assessments are conducted to measure ATR-127's effects on BAT glucose uptake and thermogenesis. Finally, diet-induced obese mice were treated with 5 mg/kg ATR-127 for 21 days to investigate the effects on glucose homeostasis, body weight, fat mass, skeletal muscle glucose uptake, BAT thermogenesis and hepatic steatosis.
RESULTS: Exposure of L6 muscle cells to ATR-127 robustly enhanced GLUT4-mediated glucose uptake despite low intramyocellular cAMP accumulation. Similarly, ATR-127 markedly increased BAT glucose uptake and thermogenesis both in vitro and in vivo. Prolonged treatment of diet-induced obese mice with ATR-127 dramatically improved glucose homeostasis, an effect accompanied by decreases in body weight and fat mass. These effects were paralleled by an enhanced skeletal muscle glucose uptake, BAT thermogenesis, and improvements in hepatic steatosis.
CONCLUSIONS: Our results demonstrate that ATR-127 is a highly effective, novel β2- and β3-ARs agonist holding great therapeutic promise for the treatment of obesity and its comorbidities, whilst potentially limiting cardiovascular complications. As such, the therapeutic effects of ATR-127 should be investigated in more detail in clinical studies.
Potassium Chloride for Injection Concentrate, USP is a sterile, nonpyrogenic concentrated solution of Potassium Chloride, USP in Water for Injection to be administered by intravenous infusion only after dilution in a larger volume of fluid.

Each mL of Potassium Chloride for Injection Concentrate contains 2 mEq of K+ and Cl– equivalent to 149 mg of potassium chloride and has an osmolarity of 4000 mOsmol/L (calc). A more concentrated Potassium Chloride for Injection Concentrate is also available. Each mL of this injection contains 3 mEq of K+ and Cl– equivalent to 224 mg of potassium chloride and has an osmolarity of 6000 mOsmol/L(calc). 

pH (4.0-8.0) may have been adjusted with hydrochloric acid and if necessary, potassium hydroxide.

Some packages are intended for multiple dose use and contain preservatives (0.05% methylparaben and 0.005% propylparaben). A summary of the available products is presented in the HOW SUPPLIED section.

Potassium Chloride for Injection Concentrate (appropriately diluted) is a parenteral fluid and electrolyte replenisher.
Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.